Ionis reports success in olezarsen trial for high triglycerides

Ionis’ Olezarsen to achieve global sales of approximately $849 million by 2032, forecasts GlobalData - GlobalData

Ionis Pharmaceuticals has announced positive topline results from the ESSENCE study evaluating Olezarsen in individuals with moderate hypertriglyceridemia who are at risk of atherosclerotic cardiovascular disease (ASCVD). Upon approval, the drug is projected to achieve global sales of approximately $849 million by 2032, according to GlobalData, a leading data and analytics company. The study met its primary endpoint, demonstrating a statisticall…

Ionis reports success in olezarsen trial for high triglycerides

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.The post Ionis reports success in olezarsen trial for high triglycerides appeared first on Clinical Trials Arena.